Zydus Lifesciences surges on getting USFDA`s final approval for Norelgestromin and Ethinyl Estradiol Transdermal System
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 643.90, up by 4.20 points or 0.66% from its previous closing of Rs. 639.70 on the BSE.
The scrip opened at Rs. 641.80 and has touched a high and low of Rs. 647.30 and Rs. 641.00 respectively. So far 12530 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.
Last one week high and low of the scrip stood at Rs. 649.40 and Rs. 624.15 respectively. The current market cap of the company is Rs. 64907.59 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.56% and 7.47% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day (USRLD: Ortho Evra Transdermal System, 150 mcg/35 mcg per day).
Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy. This is the third hormonal transdermal patch to be approved from Zydus’ generics portfolio. The transdermal patch will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad.
Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of $330 million in the United States (IQVIA MAT July 2023). The group now has 380 approvals and has so far filed over 444 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
